This morning, my doctor recommended Ozempic as a substitute for metformin to help manage blood glucose levels. Of course, she didn’t recommend I get off my ass and exercise more. Anyway, I said, “I think I’ve heard of this drug. I’m going to do some research and get back to you.”
Surely enough, I have heard of this in the form of a popular weight loss drug. So I decided to research enough to write this article.
The article below is technical, in that it merely cites results of studies. I’d also like to point out the pervasive corruption coming from Big Pharma, at least here in the USA, which includes: Lobbying and other forms of “incentivizing” of health care professionals and various government regulatory bodies, including the FDA and Congress. These forms of bribery include but are not limited to campaign contributions, high paying board appointments, dinner parties, free lunches, and air miles.
– GLP-1 receptor agonist.
– Popular diabetes and weight loss drug.
SIDE EFFECTS / RISKS
– NEW: Stomach paralysis (see source 1 and 2 in SOURCES section below).
– NEW: Intestinal obstruction: The researchers wrote that while the efficacy and safety of the GLP-1RAs are widely accepted within the medical community, the risk of intestinal obstruction—a potentially fatal condition that requires surgery—increase in type 2 diabetics, peaking around a year and a half. This “is 4.5 times higher than those receiving other glucose control medications,” the researchers wrote. See source 3 below.
– NEW: Surgery risk: Surgeons & Anesthesiologists are increasingly warning patients to stop Ozempic & other GLP-1 agonists days before surgery to prevent a severe surgical complication (aspiration pneumonia). This info is very important and should be shared with everyone taking Ozempic/Wegovy/Rybelsus/etc.
– Common side effects: nausea, stomach pain, reflux, diarrhea, vomiting, sarcopenia (reduced muscle), and constipation.
– Potential serious side effects: may increase the risk of thyroid cancer, lump in neck, difficulty swallowing, shortness of breath, difficulty breathing, upper abdominal pain, blurred vision, vision loss, dark areas in vision, shakiness, nervousness, anxiety, sweating, chills, clamminess, irritability, impatience, confusion, rapid heartrate, dizziness, decreased urination, swelling of legs, ankles, or feet, fatigue, rash, itching, shock, pancreatitis, appendicitis, gallbladder disease, low blood sugar, kidney injury, anaphylaxis, angioedema, retinal damage, and suicidal thinking or behavior.
– Risk of thyroid C-cell tumors: In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see WARNINGS AND PRECAUTIONS and Nonclinical Toxicology].